Moderna's Stock Surges on South Korea Vaccine Deal, U.S. Policy Shifts Push It to 334th in Volume

On August 12, 2025, Moderna (MRNA) rose 0.75% with a trading volume of $0.31 billion, marking a 38.58% increase from the previous day and ranking 334th in market activity. The stock’s performance was influenced by developments in the mRNA vaccine sector.

Korea’s Disease Control and Prevention Agency (KDCA) integrated Moderna’s mRNA-based COVID-19 vaccines into its national immunization program on August 5, securing 5.3 million doses from Moderna and Pfizer/BioNTech. This procurement underscores sustained demand for Moderna’s technology in public health initiatives.

Meanwhile, the U.S. government announced a phased wind-down of federal mRNA vaccine projects, including those involving Moderna and Pfizer. The decision, attributed to Health Secretary Robert F. Kennedy Jr., cited safety concerns and limited benefits for respiratory viruses. While late-stage trials may conclude, no new mRNA vaccine programs will receive federal funding. Public health experts have warned this could slow biotech innovation and pandemic preparedness.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day yielded a total profit of $2,300 from 2022 to the present. The maximum drawdown during this period was -15.7%, recorded in early 2023. This highlights the strategy’s moderate returns alongside notable risks, particularly during market volatility in February 2023.